Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia

Br J Haematol. 2012 Jan;156(1):1. doi: 10.1111/j.1365-2141.2011.08802.x. Epub 2011 Jul 25.

Authors

Vincenzo Pitini¹, Antonio Cascio, Carmela Arrigo, Giuseppe Altavilla

Affiliation

¹ Department of Medical Oncology, University of Messina, Via Consolare Valeria, 98125 Messina, Italy. [email protected]

PMID: 21790529
DOI: 10.1111/j.1365-2141.2011.08802.x

No abstract available

Publication types

Case Reports

MeSH terms

Alemtuzumab
Amphotericin B / therapeutic use
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antiprotozoal Agents / therapeutic use
Humans
Immunocompromised Host
Leishmaniasis, Visceral / complications*
Leishmaniasis, Visceral / drug therapy
Leishmaniasis, Visceral / pathology*
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Male
Middle Aged
Opportunistic Infections / complications*
Opportunistic Infections / drug therapy
Opportunistic Infections / pathology*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antiprotozoal Agents
Alemtuzumab
Amphotericin B